ES2087091T3 - Una molecula soluble relacionada pero distinta de la icam-1. - Google Patents

Una molecula soluble relacionada pero distinta de la icam-1.

Info

Publication number
ES2087091T3
ES2087091T3 ES90100557T ES90100557T ES2087091T3 ES 2087091 T3 ES2087091 T3 ES 2087091T3 ES 90100557 T ES90100557 T ES 90100557T ES 90100557 T ES90100557 T ES 90100557T ES 2087091 T3 ES2087091 T3 ES 2087091T3
Authority
ES
Spain
Prior art keywords
sicam
icam
purified
soluble
molecula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90100557T
Other languages
English (en)
Inventor
Jeffrey Greve
Alan Mcclelland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26972210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2087091(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/301,192 external-priority patent/US5235049A/en
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Application granted granted Critical
Publication of ES2087091T3 publication Critical patent/ES2087091T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Bipolar Transistors (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA FORMA SOLUBLE DE MOLECULA DE ADHESION INTERCELULAR (SICAM-1) Y SICAM-1 HUMANA PURIFICADA Y AISLADA. ESTA INVENCION TAMBIEN SE REFIERE A UNA SICAM-1 PURIFICADA Y AISLADA CON CODIFICACION DE LA SECUENCIA DE DNA. LOS DOMINIOS EXTRACELULARES DE SICAM-1 E ICAM-1 INSOLUBLE SON SUSTANCIALMENTE LOS MISMOS. ICAM-1 ESTA PRESENTE EN EL PROCESO POR EL QUE LOS LINFOCITOS SE UNEN A SUSTRATOS CELULARES DURANTE LAS INFLAMACIONES Y SIRVE COMO EL PRINCIPAL RECEPTOR DEL RINOVIRUS HUMANO (HRR). SICAM-1, POR LO TANTO, TIENE LA PROPIEDAD DE REDUCIR LA INFLAMACION INMUNE Y DE INHIBIR LA INFECCION DEL RINOVIRUS Y COXSACKIEVIRUS A.
ES90100557T 1989-01-24 1990-01-12 Una molecula soluble relacionada pero distinta de la icam-1. Expired - Lifetime ES2087091T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/301,192 US5235049A (en) 1989-01-24 1989-01-24 Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
US44595189A 1989-12-13 1989-12-13

Publications (1)

Publication Number Publication Date
ES2087091T3 true ES2087091T3 (es) 1996-07-16

Family

ID=26972210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90100557T Expired - Lifetime ES2087091T3 (es) 1989-01-24 1990-01-12 Una molecula soluble relacionada pero distinta de la icam-1.

Country Status (15)

Country Link
EP (1) EP0379904B1 (es)
JP (1) JP3080631B2 (es)
KR (1) KR100202435B1 (es)
AT (1) ATE137799T1 (es)
AU (1) AU641134B2 (es)
DE (1) DE69026844T2 (es)
DK (1) DK0379904T3 (es)
ES (1) ES2087091T3 (es)
FI (1) FI100601B (es)
GR (1) GR3020481T3 (es)
IE (1) IE74144B1 (es)
IL (1) IL93119A (es)
NO (1) NO900155L (es)
NZ (1) NZ232203A (es)
PT (1) PT92920B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
DE68929096T2 (de) * 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
US6797270B1 (en) 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
HU217792B (hu) * 1989-03-16 2000-04-28 Dana Farber Cancer Institute Eljárás intercelluláris adhéziós molekula (ICAM-1) oldható származékai és ezeket tartalmazó gyógyszerkészítmények előállítására
DK0745852T3 (da) * 1989-03-16 2002-10-14 Blood Res Center Anvendelse af funktionelle derivater af intercellulær adhæsion-molekylet ICAM-1 i antiviral terapi
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
WO1991018011A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
ES2134762T3 (es) * 1990-07-20 1999-10-16 Bayer Ag Formas multimericas de proteinas receptoras de rinovirus humanos.
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
AU710965B2 (en) * 1992-06-22 1999-09-30 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
WO1994004188A1 (en) * 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
FR2710778B1 (fr) * 1993-09-29 1995-12-01 Framatome Sa Grappe de commande pour réacteur nucléaire et réacteur en faisant application.
DE4335273A1 (de) * 1993-10-15 1995-04-20 Univ Ludwigs Albert Peptide zur Tumortherapie
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
EP0956508B1 (en) * 1997-10-02 2003-04-09 Icos Corporation Icam-4 and diagnostic uses thereof
FR2788161B1 (fr) * 1998-12-30 2001-03-23 Framatome Sa Crayon absorbant pour grappe de commande de reacteur nucleaire
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
IL145480A0 (en) 1999-03-19 2002-06-30 Genentech Inc Treatment of lfa-1 associated disorders with increasing doses of lfa-1
EP1599602B1 (en) * 2003-02-14 2015-01-14 Beth Israel Deaconess Medical Center, Inc. Predicting graft rejection
JP4671323B2 (ja) * 2004-04-28 2011-04-13 大日本印刷株式会社 ディスプレイ装置
AU2005254980A1 (en) 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE128727T1 (de) * 1987-05-04 1995-10-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
ES2064327T3 (es) * 1987-11-02 1995-02-01 Baylor College Medicine Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor
DE68929096T2 (de) * 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
AU636230B2 (en) * 1990-10-24 1993-04-22 Dolores Y. Beaupied Garment to hold an ostomy appliance

Also Published As

Publication number Publication date
PT92920B (pt) 1995-12-29
FI900331A0 (fi) 1990-01-22
ATE137799T1 (de) 1996-05-15
PT92920A (pt) 1990-07-31
IL93119A0 (en) 1990-11-05
IE74144B1 (en) 1997-07-02
FI100601B (fi) 1998-01-15
KR100202435B1 (ko) 1999-06-15
NZ232203A (en) 1992-10-28
NO900155L (no) 1990-07-25
DK0379904T3 (da) 1996-09-16
JPH0381296A (ja) 1991-04-05
AU4876790A (en) 1990-08-02
EP0379904A1 (en) 1990-08-01
GR3020481T3 (en) 1996-10-31
EP0379904B1 (en) 1996-05-08
IE900257L (en) 1990-07-24
AU641134B2 (en) 1993-09-16
IL93119A (en) 1999-07-14
JP3080631B2 (ja) 2000-08-28
KR900011895A (ko) 1990-08-02
NO900155D0 (no) 1990-01-11
DE69026844D1 (de) 1996-06-13
DE69026844T2 (de) 1996-09-12

Similar Documents

Publication Publication Date Title
ES2087091T3 (es) Una molecula soluble relacionada pero distinta de la icam-1.
CA2008368A1 (en) Soluble molecule related to but distinct from icam-1
MX9702932A (es) L-ribofuranosilnucleosidos.
ATE98376T1 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
TR199900848T2 (xx) Oksadiazoller, elde edilmeleri ve ila� olarak kullan�mlar�.
BG102241A (bg) Инхибитори на клетъчна адхезия
FI973087A7 (fi) Soluadheesion inhibiittoreita
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
FI913470A0 (fi) Multimer form av receptorprotein hos humant rhinovirus.
ES2191075T3 (es) 8-arilalquil- y 8-arilheteroalquil-5,11-dihidro-6h-dipirido-(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infecciones por hiv.
FR2422720A2 (fr) Separation et purification de proteines par chromatographie
ES2144054T3 (es) Complejos de tri(platino).
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
FI913818A0 (fi) Nytt trombolytiskt aemne.
MX9702926A (es) L-eritrosilnucleosidos.
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
GR1000156B (el) ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΝΕΩΝ ΠΑΡΑΓΩΓΩΝ ΤΡΙΚΥΚΛΙΚΩΝ ΑΜΙΝΩΝ ΤΗΣ ΤΕΤΡΑΥΔΡΟ-5,6,7,8ΝΑΦΘΟ[2,3b] ΔΙΥΔΡΟ-2,3 ΦΟΥΡΑΝΗΣ & ΤΗΣ ΤΕΤΡΑΥΔΡΟ-6,7,8,9 5Η-ΒΕΝΖΟΚΥΚΛΟΕΠΤΑ[2,3Β] ΔΙΥΔΡΟ-2,3 ΦΟΥΡΑΝΗΣ.
IT1241631B (it) "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
DK0505400T3 (da) N-substituerede naphthalimider, deres fremstilling og anvendelse
EA199800368A1 (ru) Новые промежуточные продукты и их использование для получения n,n'-мостиковых бисиндолилмалеимидов
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DZ2670A1 (fr) Nouveaux dérivés de l'échinocandine leur procédé de préparation et leur application comme anti-fongiques.
MX9702927A (es) L-piranosilnucleosidos.
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 0379904

Country of ref document: ES